The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

Angela Mae Obermiller, PharmD; and Mehmet Sitki Copur, MD
Published: Tuesday, Mar 15, 2011
While the beginnings of endocrine therapy for breast cancer can be traced to the 19th century, 1 the exact mechanisms of tumor response and resistance to endocrine manipulation still remain to be elucidated. The first truly successful targeted therapy against the estrogen receptor (ER) came with the resurrection of the compound ICI 46474, as tamoxifen, after it was initially abandoned in 1972.2 Although several endocrine therapies, including selective ER modulators, aromatase inhibitors (AIs), progestins, androgens, and luteinizing hormone-releasing hormone (LHRH) agonists, are available today, the quest for a better tamoxifen still continues. Many promising agents in the preclinical setting have not proven nearly as effective as tamoxifen in the clinical setting.3,4
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x